A5086939776- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- Systemic Sclerosis and Related Diseases
- T-cell and B-cell Immunology
- Renal Diseases and Glomerulopathies
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Cytokine Signaling Pathways and Interactions
- Liver Diseases and Immunity
- Lipid metabolism and disorders
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders Research
- Lymphoma Diagnosis and Treatment
- Peripheral Neuropathies and Disorders
- Celiac Disease Research and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Galectins and Cancer Biology
- Reproductive System and Pregnancy
- Protein Tyrosine Phosphatases
- Psoriasis: Treatment and Pathogenesis
- interferon and immune responses
- Folate and B Vitamins Research
Aristotle University of Thessaloniki
2020-2025
University of Crete
2017-2024
Hippocration General Hospital
2024
University Hospital of Heraklion
2017-2022
Cliniques Universitaires Saint-Luc
2020
ENT and Allergy
2017
Several population-based studies on systemic lupus erythematosus (SLE) have been reported, yet community-based, individual-case validated, comprehensive reports are missing. We studied the SLE epidemiology and burden island of Crete during 1999-2013.Multisource case-finding included patients ≥15 years old. Cases were ascertained by ACR 1997, SLICC 2012 criteria rheumatologist diagnosis, validated through synthesis medical charts, administrative patient-generated data.Overall...
Objectives Classification criteria are biased towards classifying long-standing disease. We compared the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)-2019, Systemic Lupus International Collaborating Clinics (SLICC)-2012 and ACR-1997 in an early (median 48 months) systemic lupus erythematosus (SLE) cohort. Methods Patients diagnosed with SLE (n=690) or control diseases (n=401). Sensitivity, specificity time-to-classification were calculated. Modified...
Diagnostic reasoning in systemic lupus erythematosus (SLE) is a complex process reflecting the probability of disease at given timepoint against competing diagnoses. We applied machine learning well-characterised patient data sets to develop an algorithm that can aid SLE diagnosis.From discovery cohort randomly selected 802 adults with or control rheumatologic diseases, clinically panels deconvoluted classification criteria and non-criteria features were analysed. Feature selection model...
In patients with LN, clinical and histological responses to treatment have been shown be discordant. We investigated whether per-protocol repeat kidney biopsies are predictive of LN relapses long-term renal function impairment.Forty-two incident biopsy-proven active proliferative (class III/IV±V) from the database UCLouvain were included in this retrospective study. Per-protocol performed after a median [interquartile range (IQR)] time 24.3 (21.3-26.2) months. The National Institutes Health...
Comorbidities and multimorbidity, often complicating the disease course of patients with chronic inflammatory rheumatic diseases, may be influenced by disease-intrinsic extrinsic determinants including regional social factors. We analyzed frequency co-segregation self-reported comorbid diseases in a community-based Mediterranean registry (n = 399) systemic lupus erythematosus (SLE). Predictors for multimorbidity were identified multivariable logistic regression, strongly-associated pairs...
To investigate whether T-bet+ B cells, as well age-associated cells/ABCs (CD19+CD21-CD11c+T-bet+) and double-negative cells/DN (CD19+IgD-CD27- CXCR5-T-bet+), serve prognostic and/or therapeutic tools for systemic lupus erythematosus (SLE) in humans. Flow cytometry was used enumerating cells ABCs/DN subsets, found the peripheral blood of 10 healthy donors 22 active SLE patients. Whole assay cultures, combined with vitro pharmacological treatments, were performed to evaluate effects...
Evidence on comorbidity prevalence in antiphospholipid syndrome (APS) and its difference from high burden rheumatic diseases is limited. Herein, we compare multiple comorbidities between APS RA.A total of 326 patients the Greek registry [237 women, mean age 48.7 (13.4) years, 161 primary (PAPS), 165 SLE-APS] were age/sex matched (1:2 ratio) with 652 a multicentre RA cohort 3115 patients. Prevalence cardiovascular (CV) risk factors, stroke, coronary artery disease (CAD), osteoporosis,...
Background Examining urban–rural differences can provide insights into susceptibility or modifying factors of complex diseases, yet limited data exist on systemic lupus erythematosus (SLE). Objective To study SLE risk, manifestations and severity in relation to urban versus rural residence. Methodology Cross-sectional analysis the Crete Lupus Registry. Demographics, residency history clinical were obtained from interviews medical records ( N=399 patients). Patients with exclusively urban,...
Cognitive impairment (CI) is one of the most frequent neuropsychiatric manifestations systemic lupus erythematosus (SLE). Given that extensive neuropsychological testing not always feasible in routine clinical practice, brief cognitive screening tools are desirable. The aim this study was to evaluate Montreal Assessment (MoCA) as a tool for CI SLE.Consecutive SLE patients followed at single centre were evaluated using MoCA and an test battery (NPT), including Digits Forward Backwards, Rey...
<h3>Objective</h3> This study aims to clarify whether T-bet<sup>+</sup> B cells, as well the sub-populations of age-associated cells/ABCs (CD19<sup>+</sup>CD21<sup>-</sup>CD11c<sup>+</sup>T-bet<sup>+</sup>) and double-negative cells/DN (CD19<sup>+</sup>IgD<sup>-</sup>CD27<sup>-</sup>CXCR5<sup>-</sup>T-bet<sup>+</sup>), serve prognostic and/or therapeutic tools for systemic lupus erythematosus (SLE) in humans. <h3>Methods</h3> Flow cytometry was used enumerate immunophenotype T-bet+ cells...
Abstract Objectives To discern predictive factors for incident kidney involvement in patients with SLE. Methods Patients SLE from the ‘Attikon’ Lupus cohort were monitored LN, defined by histology and/or classification criteria. Demographic and clinical characteristics at baseline compared against who did not develop LN. LN-free Kaplan–Meier survival curves generated. A multivariate Cox proportional hazards model was used to identify independent predictors of Independent validation performed...
Age-associated B cells (ABCs) constitute a cell subset, defined as CD19+CD21-CD11c+, that expands continuously with age and accumulates strongly in individuals autoimmune and/or infectious diseases. In humans, ABCs are principally IgD-CD27- double-negative (DN) cells. Data from murine models of autoimmunity, implicate ABCs/DN the development disorders. T-bet, transcription factor which is highly expressed these cells, considered to play major role various aspects such production...
<h3>Background</h3> Data on the efficacy of belimumab in SLE mainly originate from large randomized clinical trials, whereas reports real-life practice are lacking. <h3>Objectives</h3> To describe experience use Greece since approval drug. <h3>Methods</h3> Multicentre observational study patients receiving belimumab, with documentation disease activity (SLEDAI-2K index), achievement low states [remission (SLEDAI-2K=0) and lupus state (LLDAS)], accrual irreversible damage (SLICC index, SDI),...
The therapeutic armamentarium in Systemic Lupus Erythematosus (SLE) is expanding with the introduction of novel biologic and small-molecule agents. Complementary to randomized controlled trials, registry-based studies are advantageous due inclusion a wider range patients from daily practice potential for long-term monitoring efficacy safety therapies. Moreover, data registries can be used identify disease phenotypes that best respond agents, correlate clinical response parameters such as...
<h3>Background</h3> Long-term prospective observational studies are complementary to controlled clinical trials explore effectiveness and safety of biological therapies in practice. <h3>Objectives</h3> To study abatacept survival, reasons discontinuation responses everyday practice patients with rheumatoid arthritis (RA). <h3>Methods</h3> Prospective, single center at the Rheumatology Clinic, University Hospital Heraklion, Crete. At baseline, patient demographics, co-morbidities disease...